Zinc PCD Pharma Franchise Company
Cafoli Lifecare is a Zinc PCD pharma franchise company offering 110 Zinc formulations manufactured at WHO-GMP certified facilities — the broadest single-molecule range in our portfolio. It spans paediatric syrups and drops, dispersible and conventional tablets, dermatological ointments and dusting powders, ophthalmic preparations, injections and nutritional sachets, all available to franchise partners under exclusive monopoly rights.
What is Zinc?
Zinc is an essential trace mineral and a structural or catalytic cofactor for several hundred human enzymes and for zinc-finger transcription factors. It is required for normal immune function, protein synthesis, wound healing, growth and the maintenance of epithelial and mucosal integrity. Deficiency impairs immunity and growth and contributes to the severity of childhood diarrhoea; zinc sulfate is listed on the WHO Model List of Essential Medicines. Further clinical background is available from MedlinePlus.
Dosage Forms Available
The Cafoli Lifecare Zinc range is available as Capsule, Cream, Drop, Dry Syrup, Dusting Powder, Energy Drink, Eye Drops, Eye Ointment, Injection, Ointment, Powders/Sachet/Shots, Sachet, Soap, Softgel, Suspension, Syrup and Tablets — seventeen dosage forms across 110 SKUs.
Therapeutic Applications
Zinc is used as adjunctive therapy alongside oral rehydration salts in acute childhood diarrhoea, in the correction of zinc deficiency and in growth faltering, as supportive therapy in wound healing and post-surgical recovery, in dermatology for acne and for nappy and other dermatitis (as topical zinc oxide), and as immune and nutritional support. Ophthalmic zinc preparations are used in eye-health formulations.
Principal prescribers are paediatricians, dermatologists, general physicians, gastroenterologists and ophthalmologists.
Why Zinc is a High-Potential Molecule for Distributors
Zinc is unusual among nutritional molecules in that its largest indication is protocol-driven rather than discretionary. WHO and UNICEF recommend zinc plus ORS as standard treatment for childhood diarrhoea, and that recommendation is embedded in Indian paediatric practice. Demand therefore follows treatment guidelines and disease incidence, not marketing spend — which makes off-take unusually resilient.
The second advantage is category reach. At 110 SKUs and seventeen dosage forms, Zinc is less a single product than a portfolio: paediatric syrups and dispersible tablets for diarrhoea, topical ointments and dusting powders for dermatology, softgels and sachets for immune and nutritional support, and injections for clinical use. A single monopoly agreement therefore lets one partner call on paediatricians, dermatologists and general physicians with distinct products rather than competing for the same prescription — and the paediatric segment in particular delivers high-frequency, seasonal, volume-led turnover.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers exclusive monopoly rights by district, WHO-GMP certified manufacturing and DCGI-approved formulations. Partners receive complete promotional inputs — visual aids, MR bags, samples, prescription pads and product literature — plus transparent net rates and dependable dispatch. Cafoli Lifecare supports 1000+ franchise partners across India.
References
- MedlinePlus — Zinc in diet
- PubChem — Zinc Sulfate (CID 24424)
- WHO Model List of Essential Medicines
Our formulations of Zinc find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: